SCHEMBL4333069

SCHEMBL4333069

CCOS(=O)(=O)Oc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA9 Q16790 4/20 0.48
KMT2A Q03164 3/20 0.47
LTA4H P09960 1/20 0.41
LMNA P02545 3/20 0.40
PPARG P37231 2/20 0.40
NFE2L2 Q16236 1/20 0.40
PSIP1 O75475 1/20 0.40
HTT P42858 1/20 0.40
MEN1 O00255 2/20 0.39
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
PTPN1 P18031 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
CA4 P22748 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL15988156 0.93 CA1 (0.42) CA1CA2CA9KMT2ALTA4H
Tetrabuthylammonium SCHEMBL29003415 0.85 MLNR (0.40) CA1CA2CA9KMT2ALTA4H
SCHEMBL4336610 0.84 CA1 (0.45) CA1CA2CA9KMT2ALTA4H
SCHEMBL10442793 0.84 CA1 (0.45) CA1CA2CA9KMT2ALTA4H
Ether SCHEMBL23581122 0.83 CA1 (0.48) CA1CA2CA9KMT2ALTA4H
SCHEMBL16395075 0.83 ESR1 (0.41) CA1CA2CA9KMT2AMEN1
SCHEMBL27394660 0.82 CA1 (0.44) CA1CA2CA9KMT2ALTA4H
SCHEMBL3895027 0.82 CA2 (0.53) CA1CA2CA9KMT2APPARG
SCHEMBL777279 0.81 LTA4H (0.50) CA1CA2CA9KMT2ALTA4H
Ether SCHEMBL4275388 0.81 CA2 (0.47) CA1CA2CA9KMT2APPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3967217-B1 BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE GLOBAL GENOMICS GROUP LLC (US) 2024-08-14 EP disclosed
CN-115974730-A Method for synthesizing organic sulfate by persulfate 湖南大学 2023-04-18 CN disclosed
CN-107427528-B Glycan therapeutics and methods related thereto 卡莱多生物科技有限公司 2022-09-23 CN disclosed
US-20220102000-A1 PREDICTING BLOOD METABOLITES YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2022-03-31 US disclosed
EP-3967217-A1 BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE Global Genomics Group, LLC (US) 2022-03-16 EP disclosed
US-11196085-B2 Non-aqueous electrolytic rechargeable batteries for extended temperature range operation A123 SYSTEMS LLC (US) 2021-12-07 US disclosed
EP-2772981-B1 NON-AQUEOUS SECONDARY BATTERY ASAHI CHEMICAL IND (JP) 2020-10-21 EP disclosed
CN-105390745-B Electric storage element 株式会社杰士汤浅国际 2020-06-23 CN disclosed
EP-3650852-A1 BLOOD BASED BIOMARKERS FOR DIAGNOSING ATHEROSCLEROTIC CORONARY ARTERY DISEASE Global Genomics Group, LLC (US) 2020-05-13 EP disclosed
US-10644353-B2 Non-aqueous secondary battery ASAHI KASEI KABUSHIKI KAISHA (JP) 2020-05-05 US disclosed
US-20130224535-A1 Non-Aqueous Electrolyte Solution and Non-Aqueous Secondary Battery ASAHI KASEI E-MATERIALS CORPORATION (JP) 2013-08-29 US disclosed
US-20090304832-A1 Treatment of Parasitic Infections in Humans and Animals SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) 2009-12-10 US disclosed
EP-1030399-B1 NON-AQUEOUS ELECTROLYTE CELL MITSUBISHI CHEM CORP (JP) 2009-05-13 EP disclosed
WO-2006048734-A1 TREATMENT OF PARASITIC INFECTIONS IN HUMANS AND ANIMALS SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) 2006-05-11 WO disclosed
CN-1134083-C Nonaqueous electrolyte battery ������ѧ��ʽ���� 2004-01-07 CN disclosed
US-6670078-B1 Having current collector for positive electrode and portion of outer can contacting electrolytic solution at side of positive electrode made of valve metal or alloy thereof; excellent in low temperature characteristics and long-term stability MITSUBISHI CHEMICAL CORPORATION (JP) 2003-12-30 US disclosed
CN-1278953-A Nonaqueous electrolyte battery MITSUBISHI CHEM CORP (JP) 2001-01-03 CN disclosed
EP-1030399-A1 NON-AQUEOUS ELECTROLYTE CELL MITSUBISHI CHEMICAL CORPORATION (JP) 2000-08-23 EP disclosed
CN-1116631-A Method for producing thermoplastic styrene resin composition QIMEI IND CO LTD (CN) 1996-02-14 CN disclosed
US-4609474-A ENHANCED OIL RFECOVERY SHELL OIL COMPANY (US) 1986-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090304832-A1 Treatment of Parasitic Infections in Humans and Animals DPM1, OAT, ICMT CA1 3846/4885CA2 3263/4885CA9 3795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.